KR20230154183A - 화합물 및 방사성 표지 화합물 - Google Patents

화합물 및 방사성 표지 화합물 Download PDF

Info

Publication number
KR20230154183A
KR20230154183A KR1020237029291A KR20237029291A KR20230154183A KR 20230154183 A KR20230154183 A KR 20230154183A KR 1020237029291 A KR1020237029291 A KR 1020237029291A KR 20237029291 A KR20237029291 A KR 20237029291A KR 20230154183 A KR20230154183 A KR 20230154183A
Authority
KR
South Korea
Prior art keywords
compound
psma
formula
group
bonded
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237029291A
Other languages
English (en)
Korean (ko)
Inventor
요시후미 마야
히로아키 이치카와
유스케 히가키
마사히로 오노
심페이 이이쿠니
Original Assignee
니혼 메디피직스 가부시키가이샤
고쿠리츠 다이가쿠 호진 교토 다이가쿠
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 니혼 메디피직스 가부시키가이샤, 고쿠리츠 다이가쿠 호진 교토 다이가쿠 filed Critical 니혼 메디피직스 가부시키가이샤
Publication of KR20230154183A publication Critical patent/KR20230154183A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0404—Lipids, e.g. triglycerides; Polycationic carriers
    • A61K51/0406—Amines, polyamines, e.g. spermine, spermidine, amino acids, (bis)guanidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020237029291A 2021-03-04 2022-03-02 화합물 및 방사성 표지 화합물 Pending KR20230154183A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JPJP-P-2021-034026 2021-03-04
JP2021034026 2021-03-04
JPJP-P-2021-146833 2021-09-09
JP2021146833 2021-09-09
PCT/JP2022/009003 WO2022186311A1 (ja) 2021-03-04 2022-03-02 化合物及び放射性標識化合物

Publications (1)

Publication Number Publication Date
KR20230154183A true KR20230154183A (ko) 2023-11-07

Family

ID=83155351

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237029291A Pending KR20230154183A (ko) 2021-03-04 2022-03-02 화합물 및 방사성 표지 화합물

Country Status (8)

Country Link
US (1) US20240174622A1 (cg-RX-API-DMAC7.html)
EP (1) EP4303213A4 (cg-RX-API-DMAC7.html)
JP (1) JPWO2022186311A1 (cg-RX-API-DMAC7.html)
KR (1) KR20230154183A (cg-RX-API-DMAC7.html)
AU (1) AU2022228911A1 (cg-RX-API-DMAC7.html)
CA (1) CA3210294A1 (cg-RX-API-DMAC7.html)
TW (1) TW202302542A (cg-RX-API-DMAC7.html)
WO (1) WO2022186311A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4196175A4 (en) * 2020-08-14 2025-07-30 Clarity Pharmaceuticals Ltd RADIOPHARMACEUTICAL COMPOUNDS, THEIR USES AND PROCESSES FOR THEIR PRODUCTION
CN116285684B (zh) * 2023-05-15 2023-08-08 四川绚度眼视光科技有限公司 一种多功能超亲水涂层及其制备方法与应用
CN116870176B (zh) * 2023-08-03 2025-08-12 浙江大学 PSMA靶向的PSMA-PARPi偶联物及制备方法和应用
WO2025220711A1 (ja) * 2024-04-17 2025-10-23 日本メジフィジックス株式会社 化合物、放射性標識化合物及びその製造方法、並びに放射性医薬組成物
WO2026014283A1 (ja) * 2024-07-09 2026-01-15 日本メジフィジックス株式会社 化合物、放射性標識化合物およびその製造方法、並びに放射性医薬組成物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018098390A1 (en) 2016-11-23 2018-05-31 Cancer Targeted Technology Llc Albumin-binding psma inhibitors
WO2019075583A1 (en) 2017-10-22 2019-04-25 British Columbia Cancer Agency Branch NOVEL RADIOMETAL BINDING COMPOUNDS FOR THE DIAGNOSIS OR TREATMENT OF CANCER EXPRESSING A PROSTATE-SPECIFIC MEMBRANE ANTIGEN

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060228364A1 (en) 1999-12-24 2006-10-12 Genentech, Inc. Serum albumin binding peptides for tumor targeting
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
CA2760839C (en) 2009-05-01 2019-02-12 The Trustees Of The University Of Pennsylvania Modified compstatin with peptide backbone and c-terminal modifications
CN108699108B (zh) 2016-03-01 2022-04-08 国立大学法人千叶大学 放射性标记药物
KR102724812B1 (ko) * 2017-04-05 2024-11-01 코넬 유니버시티 영상화 및 항종양 치료요법에 유용한 조정 가능한 약동학을 갖는 삼작용성 작제물
CA3060143A1 (en) * 2017-05-24 2018-11-29 Itm Isotopen Technologien Munchen Ag Novel psma-binding agents and uses thereof
CA3086454A1 (en) 2017-09-26 2019-04-04 National University Corporation Chiba University Radioactive drug
KR102156385B1 (ko) * 2018-03-30 2020-09-15 (주)퓨쳐켐 전립선암 진단 및 치료를 위한 psma-표적 방사성의약품
US12202908B2 (en) 2018-05-17 2025-01-21 Astellas Pharma Inc. Complex having anti-human MUC1 antibody Fab fragment, peptide linker and/or ligand
MX2021004146A (es) 2018-10-10 2021-06-08 Astellas Pharma Inc Composicion farmaceutica que contiene complejo de fragmento fab de anticuerpo antihumano con sitio marcado.
KR20210116437A (ko) * 2018-11-20 2021-09-27 코넬 유니버시티 방사성핵종의 마크로사이클릭 복합체 및 암의 방사선 요법에서의 이의 용도
CA3118223A1 (en) * 2018-12-18 2020-06-25 Provincial Health Services Authority Dual mode 18f-labelled theranostic compounds and uses thereof
MX2021008230A (es) 2019-01-07 2021-08-11 Astellas Pharma Inc Conjugado que comprende ligando y fragmento fab de anticuerpo ceacam5.
MX2021013055A (es) * 2019-04-26 2021-12-10 Five Eleven Pharma Inc Inhibidores de antigenos de membrana especificos de prostata (psma) como agentes diagnosticos y terapeuticos con radionuclidos.
TWI908773B (zh) * 2020-03-04 2025-12-21 日商日本醫事物理股份有限公司 化合物及放射性標誌化合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018098390A1 (en) 2016-11-23 2018-05-31 Cancer Targeted Technology Llc Albumin-binding psma inhibitors
WO2019075583A1 (en) 2017-10-22 2019-04-25 British Columbia Cancer Agency Branch NOVEL RADIOMETAL BINDING COMPOUNDS FOR THE DIAGNOSIS OR TREATMENT OF CANCER EXPRESSING A PROSTATE-SPECIFIC MEMBRANE ANTIGEN

Also Published As

Publication number Publication date
TW202302542A (zh) 2023-01-16
AU2022228911A1 (en) 2023-09-21
CA3210294A1 (en) 2022-09-09
WO2022186311A1 (ja) 2022-09-09
JPWO2022186311A1 (cg-RX-API-DMAC7.html) 2022-09-09
EP4303213A1 (en) 2024-01-10
US20240174622A1 (en) 2024-05-30
EP4303213A4 (en) 2024-09-18

Similar Documents

Publication Publication Date Title
TWI908773B (zh) 化合物及放射性標誌化合物
TW202302542A (zh) 化合物及放射性標誌化合物
US12453787B2 (en) Dual mode radiotracer and-therapeutics
KR102951950B1 (ko) 암 진단 영상화제들
CN110740757B (zh) 新型psma-结合剂及其用途
CN102014969B (zh) 用于包括灌注成像在内的应用的造影剂
US20190388569A1 (en) Multifunctional chelators, complexes, and compositions thereof, and methods of using same
KR20250160431A (ko) 방사성 금속 표지 항체, 방사성 의약, 및 화합물
JP2014051442A (ja) 前立腺がんを診断可能な核医学イメージングプローブ
CN110072560A (zh) 用于利用基于锝的化合物标记敏感和热敏性靶向生物分子的方法
CN116940557A (zh) 化合物及放射性标记化合物
HK40092961A (en) Compound and radioactive labeling compound
HK40078050A (en) Compound and radioactive labeling compound
JP6263716B2 (ja) 悪性腫瘍のpet診断用トレーサー
AU2022270890A1 (en) Precursor and radiotracer for neuroendocrine theranostics
WO2025220711A1 (ja) 化合物、放射性標識化合物及びその製造方法、並びに放射性医薬組成物
WO2026014283A1 (ja) 化合物、放射性標識化合物およびその製造方法、並びに放射性医薬組成物
Bertin et al. Synthesis and characterization of a highly stable dendritic catechol-tripod bearing technetium-99m
CN113557037A (zh) 用于核医学和放射引导医学的诊断/治疗用途的放射性药物
HK40022705B (en) Dual mode radiotracer and -therapeutics
HK40022705A (en) Dual mode radiotracer and -therapeutics
US20140199243A1 (en) Bifunctional phosphonate chelating agents

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230829

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250207

Comment text: Request for Examination of Application